Cargando…

Lutetium-177 Prostate Specific Membrane Antigen Therapy in a Patient With Double Malignancy and Single Functioning Kidney: A Case Report

Lutetium-177 labeled with 617 types of Prostate Specific Membrane Antigen ((177)Lu PSMA-617) Radio-ligand Therapy (RLT) is an emerging modality of choice for the treatment of metastatic castration-resistant prostate carcinoma (mCRPC). After it is administered intravenously, it is excreted primarily...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naeem, Zikriya, Zahra, Umal Baneen, Numair Younis, Muhammad, Khan, Irfan Ullah, Shahid, Abubaker
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Radiation Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148966/ https://www.ncbi.nlm.nih.gov/pubmed/37131569 http://dx.doi.org/10.7759/cureus.36938

Ejemplares similares

Treatment of Advanced Metastatic Prostate Cancer Using Molecular-Targeted Therapy: Radioligand Lutetium-177 Prostate-Specific Membrane Antigen
por: Rathore, Rajni, et al.
Publicado: (2023)

Malignant Phyllodes Breast Tumor: A Rare Case of Metastasis in Skeletal Muscle Detected on 18-Fluorodeoxyglucose Positron Emission Tomography
por: Shaukat, Ubaira, et al.
Publicado: (2021)

A Review of 177Lutetium-PSMA and 225Actinium-PSMA as Emerging Theranostic Agents in Prostate Cancer
por: Alam, Mohammad R, et al.
Publicado: (2022)

Definitive Treatment of Brain Metastases From a Neuroendocrine Tumor With Peptide Receptor Radionuclide Therapy With 177Lutetium DOTATATE: A Case Report
por: Zhang, Vivian, et al.
Publicado: (2023)

Lutetium-177 Dotatate-Induced Hemolytic Anemia and Myelodysplastic Syndrome
por: Alkassis, Samer, et al.
Publicado: (2022)

Metastatic MEN1 Syndrome Treated with Lutetium-177 – A Case Report
por: Gezer, Emre, et al.
Publicado: (2019)

Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer
por: Ritawidya, Rien, et al.
Publicado: (2023)

Challenges and future options for the production of lutetium-177
por: Vogel, W. V., et al.
Publicado: (2021)

Lutetium Lu-177 Dotatate Flare Reaction
por: Salner, Andrew L., et al.
Publicado: (2020)

Lutetium-177 prostate-specific membrane antigen-617 theranostics: New therapeutic hope in metastatic castrate-resistant prostate cancer?
por: Ranjan, Satish Kumar
Publicado: (2020)

Inter-comparison of quantitative imaging of lutetium-177 ((177)Lu) in European hospitals
por: Wevrett, Jill, et al.
Publicado: (2018)

Lutetium-177-PSMA-617: A Vision of the Future
por: Chandran, Elias, et al.
Publicado: (2022)

Lutetium Lu 177 Vipivotide Tetraxetan: First Approval
por: Keam, Susan J.
Publicado: (2022)

Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals
por: Ladrière, Typhanie, et al.
Publicado: (2023)

Sentinel Lymph Node Mapping in Breast Cancer: Initial Experience of a Multidisciplinary Team
por: Yasmin, Tahira, et al.
Publicado: (2022)

First communication on the efficacy of combined (177)Lutetium-PSMA with immunotherapy outside prostate cancer
por: Digklia, Antonia, et al.
Publicado: (2022)

Lutetium-177 Prostate-Specific Membrane Antigen-617 Treatment in Metastatic Castration-Resistant Prostate Adenocarcinoma: Results of Single-Center Experience
por: Maman, Adem
Publicado: (2023)

Lutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System
por: Aslani, Alireza, et al.
Publicado: (2015)

Neuroendocrine Tumor Therapy with Lutetium-177: A Literature Review
por: Maqsood, Muhammad Haisum, et al.
Publicado: (2019)

Renal outcomes of radioligand therapy: experience of (177)lutetium—prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer
por: Gallyamov, Marat, et al.
Publicado: (2019)

Review of Lutetium-177-labeled Anti-prostate-specific Membrane Antigen Monoclonal Antibody J591 for the Treatment of Metastatic Castration-resistant Prostate Cancer
por: Niaz, Muhammad O, et al.
Publicado: (2020)

Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy
por: Ruigrok, Eline A. M., et al.
Publicado: (2020)

Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives
por: Seitzer, Konstantin Egon, et al.
Publicado: (2021)

(177)Lutetium SPECT/CT: Evaluation of collimator, photopeak and scatter correction
por: Huizing, Daphne M. V., et al.
Publicado: (2020)

Clinical Best Practices for Radiation Safety During Lutetium-177 Therapy
por: Cappon, Derek John, et al.
Publicado: (2023)

SHDB mutant functional metastatic paraganglioma: The efficacy of Lutetium-177 DOTATE
por: Erturk, Banu, et al.
Publicado: (2023)

(68)Ga-PSMA PET-CT and PSMA score affecting therapeutic decision-making in high-risk prostatic carcinoma
por: Yasmin, Tahira, et al.
Publicado: (2023)

Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617
por: Crumbaker, Megan, et al.
Publicado: (2023)

Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
por: Gadot, Moran, et al.
Publicado: (2020)

The Spontaneous Remission of Recurrent Lymph Node Metastatic Prostate Cancer With Lowering Serum Prostate-Specific Antigen Level
por: Katano, Atsuto, et al.
Publicado: (2022)

Combined biology-guided radiotherapy and Lutetium PSMA theranostics treatment in metastatic castrate-resistant prostate cancer
por: Gaudreault, Mathieu, et al.
Publicado: (2023)

Efficacy and safety of (177)Lutetium-prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer patients: First experience in West Asia – A prospective study
por: Aghdam, Ramin Akbarian, et al.
Publicado: (2019)

Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients
por: Kesavan, Murali, et al.
Publicado: (2021)

Logistical, technical, and radiation safety aspects of establishing a radiopharmaceutical therapy program: A case in Lutetium‐177 prostate‐specific membrane antigen (PSMA) therapy
por: Zoberi, Jacqueline E., et al.
Publicado: (2023)

(68)Gallium- and (90)Yttrium-/(177)Lutetium: “theranostic twins” for diagnosis and treatment of NETs
por: Werner, Rudolf A., et al.
Publicado: (2014)

(177)Lutetium-Dotatate delays decline in quality of life in patients with midgut neuroendocrine tumors
por: Strosberg, Jonathan
Publicado: (2018)

Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma
por: Gubbi, Sriram, et al.
Publicado: (2021)

In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T
por: Ruigrok, Eline A. M., et al.
Publicado: (2022)

Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation
por: Peters, Steffie M. B., et al.
Publicado: (2023)

Lutetium (177) PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy
por: Emmett, Louise, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_t8t38o0lagn5h5ctiducs0fcd5